263 products were found matching "K05098"!

CS2164 is a multi-kinase inhibitor. It inhibits VEGFR1, -2, and -3 (IC50s = 8, 7, and 9 nM, respectively), PDGFRalpha and PDGFRbeta (IC50s = 1 and 93 nM), c-Kit (IC50 = 4 nM), Aurora B kinase (IC50 = 9 nM), and CSF-1 receptor tyrosine kinase (FMS, IC50 = 7 nM). CS2164 is selective for these kinases over a panel of...

XL092 is a multi-kinase inhibitor. It selectively inhibits the receptor tyrosine kinases (RTKs) MET, VEGFR2, Axl, and Mer (IC50s = 3, 15, 5.8, and 0.6 nM, respectively) over serine/threonine kinases for which it has no activity, but does inhibit 28 other RTKs with IC50 values ranging from 3 to 54 nM, as well as...

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human VEGFR2. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human VEGFR2....

The Lumi-Verse(TM) VEGFR2 (KDR) Kinase Assay Kit is designed to measure Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase activity for screening and profiling applications, using the highly sensitive ADP-Glo(TM) as a detection reagent. The assay kit comes in a convenient 96-well format, with...

c-Raf, Ret, VEGFR2 inhibitor, potential STAT3/5 inhibitor, potential HMT inhibitor.

Soluble in DMSO. Potent protein kinase VEGFR2 inhibitor (2nm range). Binds to the pseudokinase domain of MLKL and blocks cell death by necroptosis, as well. With regards to its role in necroptosis, it is an ATP-mimetic that was shown to bind recombinant mouse MLKL pseudokinase domain, which showed inhibited...

Vascular endothelial growth factor receptor 2 (VEGFR2), also called Kinase insert Domain receptor (KDR), is a tyrosine kinase (TK) receptor for VEGFs that plays a central role in tumor angiogenesis, therefore the inhibition of VEGFR2 is a promising therapeutic strategy for inhibiting angiogenesis and tumor growth....

XL184 is an inhibitor of VEGFR2 (IC50 = 0.035 nM). It is selective for VEGFR2 over Ron, EGFR, IGF-1R, and EphA4/B4, but also inhibits c-Met, RET, c-Kit, Axl, FLT3, and Tie2 (IC50s = 1.3, 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively). XL184 (4.6 nM) inhibits VEGF-induced tubule formation in human microvascular...

Apatinib is a tyrosine kinase inhibitor that potently suppresses the kinase activity of vascular endothelial growth factor 2 (VEGFR2, IC50 = 1 nM). It is less effective against c-kit (IC50 = 429 nM), Ret (IC50 = 13 nM), and c-src (IC50 = 53 nM) and does not inhibit EGFR, Her-2, or FGFR1 (IC50s = >10 µM). Apatinib...

JK-P3 is an inhibitor of the tyrosine kinases VEGFR2, FGFR1, and FGFR3 (IC50s = 7.83, 27, and 5.18 µM, respectively). It decreases VEGF-A-induced VEGFR2 phosphorylation in human umbilical vein endothelial cells (HUVECs) when used at a concentration 10 µM. JK-P3 decreases the proliferation of HCT116, SW480, and HT-29...

SU 5402 is an inhibitor of the tyrosine kinase domains of VEGFR2, FGFR1, and PDGFRbeta (IC50s = 0.02, 0.03, and 0.51 µM, respectively). It is much less effective against other receptor tyrosine kinases. SU 5402 is commonly used to evaluate the role of FGFR1 in cellular functions.Formal Name:...

DMXAA is a xanthene which acts as a tumor vascular disrupting agent, inducing apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core. It potently activates the TANK-binding kinase 1-interferon regulatory factor 3 (TBK1/IRF3) signaling pathway in leukocytes, inducing type-I-interferon (IFN)...